

University of Massachusetts Medical School

**eScholarship@UMMS**

---

Open Access Articles

Open Access Publications by UMMS Authors

---

2019-02-05

## A Disintegrin and Metalloproteinase 9 Domain (ADAM9) Is a Major Susceptibility Factor in the Early Stages of Encephalomyocarditis Virus Infection

Lindsey E. Bazzone

*University of Massachusetts Medical School*

*Et al.*

### Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>



Part of the [Amino Acids, Peptides, and Proteins Commons](#), [Enzymes and Coenzymes Commons](#), [Immunology and Infectious Disease Commons](#), [Virology Commons](#), [Virus Diseases Commons](#), and the [Viruses Commons](#)

---

### Repository Citation

Bazzone LE, King M, MacKay CR, Kyawe PP, Meraner P, Lindstrom D, Rojas-Quintero J, Owen CA, Wang JP, Brass AL, Kurt-Jones EA, Finberg RW. (2019). A Disintegrin and Metalloproteinase 9 Domain (ADAM9) Is a Major Susceptibility Factor in the Early Stages of Encephalomyocarditis Virus Infection. Open Access Articles. <https://doi.org/10.1128/mBio.02734-18>. Retrieved from <https://escholarship.umassmed.edu/oapubs/3753>

Creative Commons License



This work is licensed under a [Creative Commons Attribution 4.0 License](https://creativecommons.org/licenses/by/4.0/).

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).



# A Disintegrin and Metalloproteinase 9 Domain (ADAM9) Is a Major Susceptibility Factor in the Early Stages of Encephalomyocarditis Virus Infection

Lindsey E. Bazzone,<sup>a</sup> Michael King,<sup>a</sup> Christopher R. MacKay,<sup>a</sup> Pyae P. Kyawe,<sup>a</sup> Paul Meraner,<sup>b</sup> Daniel Lindstrom,<sup>a</sup> Joselyn Rojas-Quintero,<sup>c</sup> Caroline A. Owen,<sup>c</sup> Jennifer P. Wang,<sup>a,d</sup> Abraham L. Brass,<sup>e,f</sup> Evelyn A. Kurt-Jones,<sup>a,d</sup> Robert W. Finberg<sup>a,d</sup>

<sup>a</sup>Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA

<sup>b</sup>Department of Microbiology and Physiological Systems (MaPS), University of Massachusetts Medical School, Worcester, Massachusetts, USA

<sup>c</sup>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

<sup>d</sup>Program in Innate Immunity, University of Massachusetts Medical School, Worcester, Massachusetts, USA

<sup>e</sup>Department of Medicine, Division of Gastroenterology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

<sup>f</sup>Peak Gastroenterology Associates, Colorado Springs, Colorado, USA

**ABSTRACT** Encephalomyocarditis virus (EMCV) is a picornavirus that produces lytic infections in murine and human cells. Employing a genome-wide CRISPR-Cas9 knockout screen to find host factors required for EMCV infection, we identified a role for ADAM9 in EMCV infection. CRISPR-mediated deletion of ADAM9 in multiple human cell lines rendered the cells highly resistant to EMCV infection and cell death. Primary fibroblasts from ADAM9 KO mice were also strongly resistant to EMCV infection and cell death. In contrast, ADAM9 KO and WT cells were equally susceptible to infection with other viruses, including the picornavirus Coxsackie virus B. ADAM9 KO cells failed to produce viral progeny when incubated with EMCV. However, bypassing EMCV entry into cells through delivery of viral RNA directly to the cytosol yielded infectious EMCV virions from ADAM9 KO cells, suggesting that ADAM9 is not required for EMCV replication post-entry. These findings establish that ADAM9 is required for the early stage of EMCV infection, likely for virus entry or viral genome delivery to the cytosol.

**IMPORTANCE** Viral myocarditis is a leading cause of death in the United States, contributing to numerous unexplained deaths in people  $\leq 35$  years old. Enteroviruses contribute to many cases of human myocarditis. Encephalomyocarditis virus (EMCV) infection causes viral myocarditis in rodent models, but its receptor requirements have not been fully identified. CRISPR-Cas9 screens can identify host dependency factors essential for EMCV infection and enhance our understanding of key events that follow viral infection, potentially leading to new strategies for preventing viral myocarditis. Using a CRISPR-Cas9 screen, we identified a disintegrin and metalloproteinase 9 domain (ADAM9) as a major factor required for the early stages of EMCV infection in both human and murine infection.

**KEYWORDS** a disintegrin and metalloproteinase 9 domain (ADAM9), encephalomyocarditis virus, functional genomic screen

Encephalomyocarditis virus (EMCV) is a nonenveloped, single-stranded RNA (ssRNA) virus in the *Cardiovirus* genus of the *Picornavirus* family known to cause myocarditis, diabetes, and neurologic and reproductive disorders in rodents and nonhuman primates (1). The virus was first isolated in 1944 from a gibbon that died suddenly from pulmonary edema and myocarditis (2) and later isolated from diseased pigs (3). Since

**Citation** Bazzone LE, King M, MacKay CR, Kyawe PP, Meraner P, Lindstrom D, Rojas-Quintero J, Owen CA, Wang JP, Brass AL, Kurt-Jones EA, Finberg RW. 2019. A disintegrin and metalloproteinase 9 domain (ADAM9) is a major susceptibility factor in the early stages of encephalomyocarditis virus infection. *mBio* 10:e02734-18. <https://doi.org/10.1128/mBio.02734-18>.

**Editor** Christine A. Biron, Brown University

**Copyright** © 2019 Bazzone et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Evelyn A. Kurt-Jones, Evelyn.Kurt-Jones@umassmed.edu, or Robert W. Finberg, Robert.Finberg@umassmed.edu.

L.E.B., M.K., and C.R.M. contributed equally to this work.

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Sarah Cherry, University of Pennsylvania; John Modlin, Bill & Melinda Gates Foundation.

**Received** 6 December 2018

**Accepted** 13 December 2018

**Published** 5 February 2019

its discovery, EMCV has been isolated globally in an extensive range of animal species (4–7). Rodents, specifically rats, are believed to be the natural reservoir hosts of EMCV, while infection of other animal species may result from occasional cross-species transmission by ingestion of contaminated food, water, or infected carcasses (8–11). EMCV has also emerged as a pathogen capable of causing large zoonotic pandemics and decimating domestic animal populations, making it an important veterinary pathogen. While human infections are rare, EMCV can cause symptomatic disease in humans, manifesting as a mild, nonspecific febrile illness (12–15). Infection is more prevalent among humans with occupational exposure to animals, particularly hunters (16–18), suggesting a strong zoonotic potential for EMCV. While serious human EMCV infections are generally rare, EMCV rapidly kills human cells such as HeLa cells as well as primary human cells in culture (19, 20).


EMCV is a well-accepted and widely used model for studying mechanisms of virus-mediated immune suppression, viral myocarditis, and insulin-dependent diabetes (21–25). However, little is known about the receptor requirements of EMCV. The virus receptor on host cells is often a key factor in influencing viral tropism for particular tissues, which subsequently results in various disease manifestations of infection. Thus, understanding viral pathogenesis often hinges on identifying the cellular molecules that the virus binds to facilitate cell entry and subsequent infection. Here, we employed a functional genomics approach to identify genes responsible for EMCV-induced lytic infection in both human and murine cells. Using a genome-wide CRISPR-Cas9 screen, we identified ADAM9 as a major EMCV dependency factor (EDF). ADAMs (a disintegrin and metalloproteinase domain) are a family of transmembrane metalloproteinases that play important roles in growth factor and cytokine signaling as well as cell-cell signaling, adhesion, and extracellular matrix remodeling (26–35). In animals, including humans, ADAM9 is ubiquitously expressed in cells of the developing heart, brain, retina, lung, fibroblasts, neutrophils, and platelets (27, 30, 34–50). Approximately half of the ADAM family members, including ADAM9, have proteolytic capabilities that modulate the activity of cytokines, chemokines, and growth factors; their associated receptors; and cell adhesion molecules (27, 35, 37, 45). ADAMs have been implicated in a range of human cancers, inflammatory diseases, wound healing, and microbial infections; however, very little is known about the role of ADAMs in viral infection. This study demonstrates that ADAM9 functions as a major EDF involved in the early infection of both human and murine cells.

## RESULTS


**CRISPR-Cas9 screening identifies EMCV dependency factors (EDFs).** EMCV infection is rapidly lytic in human and murine cells (51–54). We took advantage of the high lytic potential of EMCV and the power of CRISPR genetic screening (53, 55) to discover virus-host interaction genes that mediated virus infection and, thus, rendered the cells susceptible to EMCV-induced cell death. HeLa cells stably expressing Cas9 were used for screening (53, 55). In initial optimization experiments, we determined that HeLa cells were killed by EMCV within 24 h of infection at a multiplicity of infection (MOI) of  $\geq 0.1$ . The rapid lysis of HeLa cells with EMCV infection allowed us to screen for EDFs using pooled single-guide RNAs (sgRNAs) since we could identify such mutant cells by their resistance to EMCV-induced cell death, i.e., these mutants would no longer be susceptible to EMCV infection and would survive EMCV challenge.

We screened for EDFs using a CRISPR-Cas9 pooled human gene screen (Fig. 1). H1-HeLa cells (stably expressing a human-codon optimized *Streptococcus pyogenes* Cas9) were transduced with the GeCKOv2 sgRNA library (53, 54), a complex lentiviral library that targets 19,052 human genes. The GeCKOv2 library contains six unique sgRNAs per gene in two half-libraries (A and B). Libraries A and B each contain three unique sgRNAs per gene, and the lentiviral libraries were transduced in parallel into H1-HeLa cells. Stable sgRNA-expressing cells were selected with puromycin for 48 h to allow sgRNA-guided CRISPR-Cas9-mediated gene deletion within each pool. The CRISPR-Cas9-sgRNA-transduced H1-HeLa cells were then infected with EMCV ATCC


## A. CRISPR-Screen for EMCV dependency factors



## B. Recovered sgRNA guide sequences



## C. Sites targeted by ADAM9 sgRNA guides



**FIG 1** CRISPR-Cas9 knockout screen for EDFs. (A) HeLa cells expressing Cas9 were transduced with the GeCKOv2 sgRNA library, and guide sequences were retrieved from cells that survived multiple rounds of EMCV infection. (B) ADAM9 sgRNA sequences were highly represented in recovered clones; 6 of the 6 sgRNAs targeting ADAM9 were present in recovered clones. GeCKOv2 screen results for genes conferring susceptibility to EMCV-induced cell death. Of the pooled CRISPR-targeted genes, ADAM9- and PA2G4-targeted guide sequences accounted for ~70% and ~22%, respectively. (C) Domain structure and sites targeted by sgRNAs.

strain VR-129B (MOI of 10). Surviving cells in each pool (<5% of the starting population) were collected 5 days postinfection, rechallenge with EMCV, and cultured for an additional 7 days (Fig. 1A). After two rounds of EMCV selection, genomic DNA was recovered from the surviving cells and sgRNA sequences were amplified from integrated proviruses by PCR and deep sequenced as described previously (53).


The screen was performed twice, and seven candidates (ADAM9, PA2G4, C1GALT1C1, C1GALT1, SLC39A9, TMEM165, and CELF1) were highly enriched in replicate pools

(Fig. 1B). The top candidate in each pool in replicate experiments was ADAM9, with 6 of 6 sgRNA sequences targeting ADAM9 being significantly enriched ( $>600$  reads) (Fig. 1B). ADAM9 sgRNAs were highly enriched in both library A and library B pools. Overall, ADAM9 sgRNAs accounted for  $>70\%$  of the overrepresented ( $>20$  reads) sgRNAs recovered from EMCV-resistant cells. The second most abundant candidate was PA2G4, which accounted for  $>22\%$  of the overrepresented sgRNAs. ADAM9 belongs to the ADAM family of type I transmembrane proteins in the zinc-dependent metalloproteinase (MP) superfamily and is comprised of 6 different domains each with distinct functions: (i) a prodomain that maintains the MP domain in latent form; (ii) an MP domain; (iii) a disintegrin domain, which binds integrins to regulate cell-cell or cell-matrix interaction and/or cell migration; (iv) a cysteine-rich and epidermal-like growth factor (EGF) domain, thought to promote cell-cell fusion and/or regulate cell adhesion; (v) a transmembrane domain, which anchors to the cell surface; and (vi) a cytoplasmic tail involved in intracellular signaling (Fig. 1C).

**ADAM9 is required for EMCV-induced cell death and virus replication in human and murine cells.** To determine the role of ADAM9 in EMCV infection, we used CRISPR-Cas9 and ADAM9-specific sgRNAs to disrupt ADAM9 expression in HeLa and HEK293T human cell lines. WT and ADAM9-deficient cloned cells were tested for their susceptibility to EMCV-induced cell death by assessing cellular ATP levels in a luciferase-based assay as a measure for cell viability. ADAM9 KO clones were resistant to EMCV infection compared to their WT counterparts (Fig. 2). WT and ADAM9 KO cells were challenged with EMCV over a range of MOIs, and cell viability and EMCV replication were measured after 24 h (Fig. 2). WT HeLa cells were sensitive to EMCV-induced cell death at MOIs of  $\geq 0.1$  (Fig. 2A). In contrast, ADAM9 KO HeLa cells were protected from EMCV-induced cell death even at MOIs of 10. At an MOI of 1, ADAM9 KO HeLa cells were  $>99\%$  viable while  $<1\%$  of WT HeLa cells survived EMCV challenge. We also examined EMCV-induced cell death in HEK293T cells (Fig. 2C). WT HEK293T cells were very sensitive to EMCV-induced cell death at all MOIs, with  $\leq 5\%$  survival of cells at doses as low as an MOI of 0.001. In contrast, ADAM9 KO HEK293T cells survived EMCV challenge at doses up to an MOI of 10. Thus, loss of ADAM9 expression rendered HEK293T cells  $>6$  logs less sensitive to EMCV-induced cell death than WT cells. We confirmed the role of ADAM9 in EMCV infection by measuring virus replication by plaque assays of culture supernatants. Replication of EMCV was markedly reduced in ADAM9 KO compared to WT cells, suggesting that ADAM9 might be required for EMCV binding and/or entry or post-entry transcription of the viral genome (Fig. 2B and D).

We next asked if ADAM9 was required for EMCV infection of primary murine cells. Primary lung fibroblasts (pLF) from mice with targeted deletion of ADAM9 (43) and their WT C57BL/6 counterparts were challenged with EMCV. WT pLF were susceptible to EMCV-induced cell death (Fig. 2E) and produced high titers of EMCV (Fig. 2F). In contrast, ADAM9 KO pLF were highly resistant to EMCV killing and were unable to support EMCV replication. At the highest MOI tested, ADAM9 KO pLF demonstrated some limited EMCV replication, but production of infectious EMCV virions was severely attenuated with an approximately 4-log decrease in infectious virion production (PFU) by ADAM9 KO compared to WT cultures. These results suggest that murine ADAM9, like human ADAM9, plays a major role in EMCV-specific lytic infection of cells.


**The requirement for ADAM9 in EMCV-induced cell death is not strain specific.** Previous EMCV studies suggest that different strains of EMCV may bind to different receptors and that some EMCV strains may use multiple pathways (56, 57). In addition, EMCV strains with different tissue tropism have been identified (1). To determine if the requirement for ADAM9 was EMCV strain specific, we infected WT and ADAM9 KO immortalized mouse lung fibroblasts (iLF) either with EMCV VR-129B (ATCC) or with EMCV-M strain (VR-1479, ATCC). ADAM9 KO cells were resistant to both EMCV strains, while WT cells were susceptible (Fig. 3A and B). We also tested if ADAM9 deficiency had an impact on replication of other RNA and DNA viruses. WT and ADAM9 KO HeLa cells were challenged with Coxsackie virus B3 (CVB3), vesicular stomatitis virus (VSV), influenza A virus (IAV), or herpes simplex virus 1 (HSV-1). WT and ADAM9 knockout cells



**FIG 2** ADAM9 is a major dependency factor for EMCV infection of human and mouse cells. WT and ADAM9 KO HeLa cells (A and B) and HEK293T cells (C and D) and two independent sets of primary lung fibroblasts (pLF) isolated from WT and ADAM9 KO mice (E and F) were incubated in medium alone or infected with EMCV at various multiplicities of infection (MOI) for 1 h at 37°C, washed to remove free virus, and cultured for 24 h at 37°C. Cell viability (A, C, and E): ATP was quantified in the cell monolayers using CellGlo reagent, revealing that ADAM9 KO cells are highly resistant to EMCV-induced cell death. Virus replication (B, D, and F): EMCV viral titers, measured on BHK21 monolayers and expressed as PFU per ml cell supernatant, showed only small amounts of replicating virus in ADAM9 KO cells. Cell viability data are mean  $\pm$  SD from 3 replicate wells; plaque assay data are mean  $\pm$  SD from 2 replicate wells at each dilution. Biological replicate experiments were performed at least twice with similar results.

were equally susceptible to infection with CVB3, VSV, IAV, and HSV-1 (Fig. 3C to F). Cells infected with VSV showed equal yields of infectious VSV from WT and ADAM9 KO pLF (Fig. 4C), suggesting that ADAM9 deficiency did not globally impact RNA virus replication.






**FIG 3** ADAM9 is required for EMCV infection but does not affect infection by other RNA or DNA viruses. WT and ADAM9 KO cells, including immortalized lung fibroblasts (iLF) and HeLa cells, were challenged with EMCV VR-129B (A), M-variant VR-1479 (B), Coxsackie virus B3 (CVB3) (C), vesicular stomatitis virus (VSV) (D), influenza A virus (IAV) (E), or herpes simplex virus 1 (HSV-1) (F) at various MOIs or incubated in medium alone for 1 h at 37°C. Cell monolayers were washed to remove free virus and incubated for 24 h at 37°C. Viability of infected cells relative to uninfected (medium-only) controls was determined with a CellGlo ATP assay and is expressed in relative luciferase units (RLU). Data are mean  $\pm$  SD from 3 replicate wells. Biological replicate experiments were performed at least twice with similar results.

#### **ADAM9 is essential for EMCV infection but is not directly involved in post-entry replication of viral genomes in the cytosol.**

To determine whether ADAM9 is required for virus binding/entry and/or required at a later step in virus replication post-entry, we transfected infectious EMCV viral RNA (vRNA) into iLF using Lipofectamine, thus bypassing the requirement for receptor-dependent entry events. iLF were either infected with intact EMCV virions for 1 h at 37°C, washed to remove residual free virus, and cultured for 18 h at 37°C (Fig. 4A) or transfected with EMCV vRNA in Lipofectamine and incubated at 37°C (Fig. 4B). iLF were also infected with VSV, as a positive control, for 1 h at 37°C, washed, and cultured (Fig. 4C). After 18 h, culture supernatants were harvested, and viral replication was determined by quantifying infectious virions in culture supernatants by plaque assay. EMCV infection of WT cells



**FIG 4** ADAM9 is required for EMCV infection but is not directly required for genome replication in the cytosol. WT and ADAM9 KO immortalized lung fibroblasts (iLF) were incubated with EMCV for 1 h at 37°C and washed (A), transfected with EMCV viral RNA (vRNA) in Lipofectamine (B), or incubated with VSV (C). Culture supernatants were harvested after 18 h. Virus replication was measured by quantifying PFU on BHK-21 cells. Data shown are mean  $\pm$  SD from 3 replicate wells. \*\*\*,  $P < 0.0001$ , WT versus ADAM9 KO.

resulted in productive infection of cells (at least 8 logs within 18 h), while infection of ADAM9 KO cells resulted in no virus production (Fig. 4A). When receptor-mediated cell entry is bypassed by transfection of infectious vRNA directly into the cell, EMCV is capable of replicating in both WT and ADAM9 KO cells (Fig. 4B). Together, these results demonstrate that ADAM9 is not directly involved in EMCV replication steps post-entry but rather facilitates EMCV entry and/or genome delivery into the cell where EMCV vRNA genomes are replicated in an ADAM9-independent manner.

**Rescue of ADAM9 in KO cells restores susceptibility to EMCV.** We next examined if rescue of ADAM9 expression to ADAM9 KO cells restores EMCV susceptibility. ADAM9 KO and WT HeLa and mouse iLF cells were transduced with retroviral vectors to express murine ADAM9 (mADAM9) or GFP as a control. Transduced cells were selected and cloned by limiting dilution. Expression of ADAM9 was confirmed by Western blot analysis (Fig. 5A). ADAM9 KO cells rescued with intact wild-type (WT) mADAM9 became susceptible to EMCV-induced cell death (Fig. 5B), demonstrating that ADAM9 is both necessary and sufficient to confer EMCV susceptibility.


ADAM9 is a multifunctional protein and has several domains that participate in a variety of cell processes. ADAM9 controls receptor-mediated signaling via the proteolytic function of its MP domain and signals via its SH3 domains in the cytoplasmic tail. To determine if mutating the MP domain of ADAM9 impacts susceptibility to EMCV, we rescued ADAM9 KO cells with an enzyme-dead mutant ADAM9 containing a Glu-to-Ala (E>A) substitution in the MP active site (58). The MP mutant ADAM9 restored EMCV susceptibility to KO cells (Fig. 5B and C). Thus, EMCV susceptibility in KO cells rescued with (E>A) mutant was indistinguishable from rescue with WT ADAM9, indicating that the active MP domain is not required for EMCV entry into cells. We next asked if the intracellular signaling domain of ADAM9 was necessary to render cells susceptible to EMCV. We replaced the cytosolic domain of ADAM9 with a V5-epitope tag and expressed the cytoplasmic-tail-deleted ( $\Delta$ CT) mutant in KO cells (Fig. 5B and C). EMCV susceptibility was restored with ADAM9- $\Delta$ CT rescue, suggesting that the cytoplasmic tail of ADAM9 does not play a role in EMCV susceptibility.

We also challenged WT, ADAM9 KO, and rescued KO cells with various doses of CVB3. As shown in Fig. 5B, we did not observe any differences in susceptibility to CVB3 infection in WT, KO, and rescued cells, confirming that ADAM9 is specifically required for EMCV infection.

## DISCUSSION

Forward genetic screens allow an unbiased and comprehensive approach to discovering host factors that promote or restrict virus replication. Recent advances in CRISPR-Cas9 have allowed highly efficient generation of knockout cells with marked





**FIG 5** Rescue of ADAM9 expression restores EMCV replication in ADAM9 KO cells. WT and ADAM9 KO HeLa cells were transduced with retroviral vectors with wild-type (WT) murine ADAM9 (mADAM9), catalytically inactive mutant ADAM9 (E>A), cytoplasmic-tail-deleted ( $\Delta$ CT) ADAM9 constructs, or GFP control vectors. (A) WT, KO, and rescue cell lysates were analyzed by Western blot using two different ADAM9 antibodies. Top panel, rabbit anti-human ADAM9 that detects an epitope in the intracellular domain of human ADAM9 and cross-reacts with mouse ADAM9 (black asterisk). Middle panel, goat anti-mouse ADAM9 that detects the extracellular domain of murine ADAM9 but not human ADAM9 (blue asterisk). Bottom panel, anti-actin which detects both human and murine  $\beta$ -actin. Top panel, WT but not KO cells expressed human ADAM9. Middle panel, rescue but not KO cells expressed murine ADAM9. Bottom panel, actin loading control. (B) WT clones, ADAM9 KO clones, and rescued ADAM9-expressing clones were infected with EMCV or CVB3 at various MOIs and incubated at 37°C for 24 h. Viability of EMCV-infected and CVB3-infected clones was measured by CellGlo ATP luminescence. (C) EMCV replication was quantified in infected culture supernatants by plaque assay. Neither the functional sequence of the ADAM9 metalloproteinase domain nor the cytoplasmic tail is required for EMCV infection. \*\*\*,  $P < 0.0001$ , KO versus WT and KO versus rescue.

phenotypes for the identification of virus dependency factors with very few false-positive hits. CRISPR-Cas9 screens using multiplexed pools of sgRNAs that cover the entire human genome have proved to be a powerful technologic advance and have been successfully used to identify receptors and other cellular dependency factors for several viruses, including influenza A virus, Zika virus, West Nile virus, dengue virus, and hepatitis C virus (53, 54, 59–61; reviewed in reference 55).

In the present study, we employed a genome-wide CRISPR-Cas9 screen to identify EDFs. The screen recovered multiple host factors, including those involved in the posttranslational modification of cell surface proteins (C1GALT1C1, C1GALT1, TMEM165), cellular proliferation (PA2G4), the regulation of mRNA processing (CELF1), and the

metalloproteinase ADAM9. We focused on ADAM9 because it was the most strongly enriched candidate in the screen and scored with multiple orthologous sgRNAs. Using a diverse panel of CRISPR-engineered ADAM9 KO human cell lines, as well as primary and immortalized murine cell lines from ADAM9 KO mice, we confirmed ADAM9's involvement in EMCV infection and demonstrated that loss of ADAM9 results in a profound block to the early stages of EMCV infection. To our knowledge, this study is the first to define a direct role for ADAM proteins in EMCV infection.

Previous studies have suggested different proteins that may be involved in susceptibility to EMCV, but definitive proof (including reconstitution of knockout cells) has not been forthcoming. For example, vascular cell adhesion molecule 1 (VCAM-1), a member of the immunoglobulin superfamily, found on primary vascular endothelial cells has previously been reported as a receptor for the EMC-D strain (62). However, cells lacking VCAM-1 have also been shown to be susceptible to EMCV infection via a yet-uncharacterized 70-kDa glycoprotein hypothesized to be responsible for mediating virus binding and attachment in these cells (56). Infection of human cardiomyocytes with two different strains of EMCV demonstrated a requirement for sialic acid and heparan sulfate in one EMCV strain but not the other, raising the possibility that different EMCV strains may bind to different polysaccharides in order to initiate infection (57). While different molecules have been implicated as receptors or attachment factors for specific strains of EMCV, the provenance of these strains has been difficult to authenticate, and we have not been able to obtain many of the strains previously reported to have specific receptor or attachment requirements. However, in this study, we were able to confirm that the two ATCC strains of EMCV both use ADAM9 as their major dependency factor. ADAM9 is likely the 70-kDa putative EMCV receptor identified by Jin et al. (56). Furthermore, we showed that the dependency on ADAM9 for infection is unique to EMCV, as infection with other RNA and DNA viruses was not affected by ADAM9 deficiency. Thus, although previous studies have identified certain cell surface molecules as potential EMCV receptors or EDFs, this is the first report of a definitive, widely expressed cell surface protein utilized by multiple EMCV strains that is critical for EMCV infection. Future experiments will be necessary to define the role of ADAM9 and other cell surface proteins as binding or entry receptors or receptor cofactors for EMCV variant strains, as the use of alternative receptors or attachment proteins may impact tissue tropism and ultimately EMCV pathogenesis.

ADAMs have been shown to regulate receptor signaling through a variety of mechanisms, many of which involve the catalytically active MP domain (27, 28, 30, 31, 33, 35, 42, 63–65). This raises the possibility that ADAM9 may function as a cofactor for EMCV infection. Given the multifunctional domains of ADAMs, it is also possible that ADAM9 plays a role in the immune response to EMCV infection following virus entry, for example, by delivering the viral genome to intracellular innate immune sensors, triggering an appropriate antiviral response. Alternatively, it is also possible that ADAM9 may be involved in innate immune evasion by EMCV, such as allowing EMCV to enter the cell undetected or by skewing the innate antiviral signaling pathways. Of ADAM9's multiple domains, we initially hypothesized that the enzymatically active MP domain and the intracellular cytoplasmic domain containing SH3 binding domains might be involved in EMCV infection. However, our rescue experiments showed that neither the metalloproteinase activity nor the cytoplasmic tail of ADAM9 is necessary to support lytic EMCV infection. Furthermore, the finding that EMCV infection does not require a catalytically active proteinase domain suggests that ADAM9 may not act as a proteolytic cofactor and further supports a direct virus-receptor interaction between ADAM9 and EMCV or a nonenzymatic protein-protein interaction of ADAM9 with the EMCV receptor that is required to facilitate virus entry.

Our data support that ADAM9 is a crucial protein for EMCV infection; specifically, ADAM9 knockout cells from two mammalian species are not infected by two different EMCV strains, reconstitution of ADAM9 permits EMCV infection, and virus replication is unaffected by ADAM9 deficiency when viral RNA is transfected directly into the cytosol. EMCV may directly bind to ADAM9, but we and others (57) have observed

polysaccharide-related binding that may facilitate productive infection. Also, as a disintegrin, ADAM9 is known to affect expression of other cell surface proteins (27, 38); thus, expression of ADAM9 could lead to uncovering of another protein that is the actual binding “receptor” protein. Since various domains and functions of ADAM9 have been identified, future experiments will yield a fuller definition of how ADAM9 facilitates entry of EMCV into the cell.

In addition to ADAM9, our CRISPR-Cas9 screen in HeLa cells identified another gene, *PA2G4*, which is likely involved in EMCV susceptibility (Fig. 1). The *PA2G4* gene encodes proliferation-associated protein 2G4, also known as ErbB3-binding protein 1 (EBP1), which plays a role in cell signal transduction, transcription, and translation and has been shown to suppress growth in certain cancers, including breast and prostate cancers (66–72). How EBP1 affects EMCV susceptibility and its relationship to ADAM9 is under investigation.

The discovery of ADAM9 as a surface protein required for EMCV infection has significant implications for our understanding of virus-host interactions and downstream effects of EMCV infection. We are defining ADAM9's precise role in downstream aspects of EMCV infection. Detailed insight into the mechanism of the EMCV-ADAM9 interaction is crucial to understanding viral pathogenesis. Functional studies examining mechanisms of EMCV binding and entry and potential for ADAM9-mediated cell signaling and cytokine production in response to EMCV infection are currently being explored.

## MATERIALS AND METHODS

**GeCKOv2 library screen.** H1-HeLa cells expressing the GeCKOv2 CRISPR library (Agilent) were plated for full coverage of the library (both pools A and B). These cells were challenged with EMCV at an MOI of 10 until <5% of living cells remained. The cells were washed and replated for another challenge of EMCV for confirmation of resistance. gDNA was isolated by expanding the remaining cells and using the Qiagen DNeasy Blood and Tissue kit on  $2 \times 10^6$  cells. PCR was performed with lentiGP-1\_F and lentiGP-3\_R (sequences below) with the product spanning the sgRNA guide sequences. This PCR product was processed and sequenced using the Illumina NextSeq 500. The library screen was performed twice for each pool of the GeCKOv2 library.

**Cell viability assay.** Cells were plated at 5,000 cells per well in duplicate on a 96-well flat-bottomed plate and incubated overnight at 37°C. The cells were challenged with virus at the respective MOI for 1 h and washed with PBS, and 150  $\mu$ l of fresh complete medium was added to each well. The plates were incubated for 24 h postinfection at 37°C, 10% CO<sub>2</sub>. The medium supernatants were collected, and 50  $\mu$ l of fresh medium and an equal volume of room-temperature CellTiter Glo reagent (Promega G7571) were added to each well and mixed for 2 min at 300 rpm. The reaction mixture was allowed to equilibrate for 10 min, and then 80  $\mu$ l of the reaction mixture was transferred to an opaque 96-well plate and the signal was detected by a luminometer.

**CRISPR KO.** ADAM9 KO lines were created using CRISPR technology. HeLa cells (H1 cell line) and 293T cells with stable expression of Cas9 (53) were transiently transfected with ADAM9 CRISPR guide RNA no. 1 (CACTGACCATCCCAATATAC) and no. 3 (CTTATGAAATTATAACTCT) from GenScript. sgRNA guide sequences were based on the GeCKO library designed by Feng Zhang's laboratory at the Broad Institute; see <http://genome-engineering.org/gecko/>. Cells were incubated for 3 days at 37°C to allow Cas9-mediated gene deletion. Cells were screened by limiting-dilution cloning. Knockout clones were validated by Western blotting.

**ADAM9 constructs.** All mouse ADAM9 constructs were made using a Gibson assembly strategy. The pQCXIP vector (53) was cut with NotI restriction enzyme. Two-step PCR of pcDNA mouse ADAM9 WT and E>A for full-length ADAM9 (Blobel lab) (mAdam9FL-F; mAdam9FL-R primer sequences below) was done using Phusion high-fidelity master mix (New England Biolabs M0531) as recommended by the manufacturer. The template for the PCR for the  $\Delta$ CT mutant was the pcDNA mouse ADAM9 WT plasmid (mAdam9FL-F; mAdam9dCT-R primer sequences below) where the reverse primer added a V5 tag as above, and a V5-pQCXIP Gibson adaptor (V5-pQCXIP sense primer sequence below) added the stop codon to the end of the transmembrane domain, replacing the intracellular domain. The PCR products were purified (Qiagen). Gene assembly was done with Gibson assembly master mix (New England Biolabs E2611) per instructions of the manufacturer into the pQCXIP retroviral backbone. Stbl3 One Shot competent cells (ThermoFisher) were transformed with the Gibson assembly product. Minipreps were made from single colonies of transformed bacteria and sequenced. Maxipreps of the sequenced plasmids were made and purified using the Qiagen HiSpeed Maxi kit.

**Rescue cell lines.** ADAM9 rescue of the knockout cell lines was done by transduction. Retrovirus was made using 293FT cells transfected with retroviral transfer constructs with a pQCXIP backbone (GFP, Addgene catalog no. 73014; mouse Adam9 WT; mouse Adam9 E>A; mouse Adam9  $\Delta$ Cytoplasmic tail), pMD 2.G, and VSV-G packaging plasmid using TransIT-293 transfection reagent (Mirus 2704) per protocol (53). After 24 h, the medium was replaced with complete DMEM. At 24 h and 48 h, supernatant was

collected (and replaced with complete DMEM as needed) and filtered through an 0.45- $\mu$ m filter. Virus supernatants were used immediately or frozen at  $-80^{\circ}\text{C}$  in single-use aliquots.

Cell lines to be rescued were plated on 6-well plates and incubated overnight prior to retroviral transduction. Culture medium was replaced with fresh complete DMEM, and retroviral supernatant was added dropwise to wells. Cells were incubated at  $37^{\circ}\text{C}$  for 2 to 3 days. Transduced cells were cloned by limiting dilution into 96-well plates and grown at  $37^{\circ}\text{C}$ . Cloned mouse ADAM9 rescue cell lines were confirmed by Western blotting and genomic DNA sequencing.

**Isolation of mouse pLF and backcrossing of KO mice.** All procedures conducted on mice were approved by the Brigham and Women's Hospital Institutional Animal Care and Use Committee. Lung fibroblasts were isolated from C57BL/6 WT and ADAM9 KO mice that were in a pure C57BL/6 background. Primary lung fibroblasts were generated from 6- to 10-week-old mice according to a protocol adapted from Yamamoto et al. (73). Euthanized mice were washed with 90% ethanol to reduce contamination. Whole-lung lobes were dissected and placed into sterile PBS. Lungs were then submerged in 70% ethanol for 20 s and then placed into digestion medium (DMEM with 0.25% trypsin) and cut into small pieces using a sterile scalpel. The lung pieces were then transferred into 10 ml of digestion medium and incubated with shaking at  $37^{\circ}\text{C}$ . After 30 min, 5 ml of cold complete DMEM (DMEM, 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin, 250 ng/ml amphotericin B) was added, and the cells were centrifuged for 5 min at  $350 \times g$  at  $4^{\circ}\text{C}$ . The cell pellet was removed and resuspended in fresh complete DMEM. For each mouse, the lung pieces and cells were resuspended in 50 ml of complete DMEM and then plated in a 225- $\text{cm}^2$  tissue culture flask. The cells were incubated for 10 to 15 days with minimal disruption, with fresh medium added after 7 days. For the first passage, the cells and lung pieces were detached from the flasks by scraping and separated into cells and lung pieces with a 70- $\mu\text{m}$  cell strainer. The single-cell suspension was either passaged one or two times when 90% confluent in complete DMEM or used immediately for stimulation. Fibroblasts were immortalized with SV40.

**Viruses.** EMCV VR-129B, EMCV-M VR-1479, and VSV strain Indiana were obtained from the American Type Culture Collection (ATCC). IAV WSN/33 was obtained from A. L. Brass (74). HSV-1 KOS was a gift from David Knipe (Harvard Medical School). CVB3 Nancy stocks were from Robert Finberg.

**Preparation of EMCV vRNA.** EMCV vRNA was isolated from ultrapure EMCV stocks using the QIAamp viral RNA Mini kit (Qiagen) according to the manufacturer's protocol. Viral RNA concentration was determined by NanoDrop, and vRNA stocks were stored at  $-20^{\circ}\text{C}$  until use. Cells were transfected with viral RNA at 100 ng/well with 0.5  $\mu\text{l}$  of Lipofectamine 2000 (ThermoFisher Scientific catalog no. 11668027). After 1 h of transfection, the cells were washed, trypsinized, and diluted into BHK-21 cells as described above.

**Plaque assay.** BHK-21 cells were plated on 12-well plates at  $7 \times 10^5$  cells/well and incubated overnight at  $37^{\circ}\text{C}$  to allow formation of intact monolayers. Cell growth medium was removed and replaced with 450  $\mu\text{l}$  per well of fresh complete DMEM with 10% FBS. Viral supernatant samples were thawed on ice, and 10-fold serial dilutions of virus were performed in serum-free DMEM. Diluted supernatants were added to intact BHK-21 monolayers in duplicate at 50  $\mu\text{l}$  per well and mixed by gentle plate shaking (final dilutions between  $10^{-2}$  and  $10^{-7}$ ). Cells were incubated at  $37^{\circ}\text{C}$  for 1 h, with gentle shaking every 20 min. After 1 h, virus dilutions were removed by aspiration, and cell monolayers were washed with  $1 \times$  PBS to remove unbound virus. An agarose overlay was added to each well and allowed to solidify at room temperature. Plates were then incubated at  $37^{\circ}\text{C}$  for 24 h. Cells were then fixed/stained by adding crystal violet dissolved in 4% paraformaldehyde (0.5% crystal violet [(Sigma), 4% paraformaldehyde [Sigma] in PBS [Corning]) at room temperature for at least 2 h. Overlays were removed, and plaques were counted. PFU/ml was calculated by averaging the number of plaques in the duplicate wells and dividing by the product of the dilution factor and volume applied to the assay wells.

**Primers.** Primer sequences were as follows: lentiGP-1\_F, 5'-AATGGACTATCATATGCTTACCGTAACTT GAAAGTATTTTCG-3'; lentiGP-3\_R, 5'-ATGAATACTGCCATTTGTCTCAAGATCTAGTTACGC-3'; mAdam9FL-F, 5'-CGCTGCAGGAATTGATCCGCGGCTCCGGCTGCAGGAATTC-3'; mAdam9FL-R, 5'-CGAGGCTACCGGTG CGGCCGAGCGCGCCAGTGTGATGGAT-3'; mAdam9 $\Delta$ CT-R, 5'-TAATCGTCCCTTGTGCGGCTGCCATT TTCCTCTTTATCAAGGGTAAGCCTATCCCTAACCTCTCCTCGGTCTCGATTCTACG-3' (V5 tag in bold); V5-pQCXIP (sense), 5'-CCCTCTCCTCGGTCTCGATTCTACGTGATAGTACCGGTAGGCCTCGTACGC-3'.

**Western blotting.** Following trypsinization, cells were lysed with RIPA buffer with protease inhibitor cocktail (Sigma P8340) incubated at room temperature for 10 min. The lysate was cleared by centrifugation at 15,000 rpm for 10 min to remove cell debris. The concentration of the lysates was determined by BCA assay (ThermoFisher PI23227). Twelve percent precast gels (Bio-Rad 4561044) were loaded equally with lysate and run at 80 V. The proteins were transferred to a PVDF membrane (Bio-Rad 1620219) with a semidry transfer system (Bio-Rad 1703940) for 60 min at 25 V (300 mA maximum). The membrane was blocked with 3% BSA or 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBS-T) for at least 1 h. Incubation of the membrane with primary antibodies was done overnight at  $4^{\circ}\text{C}$  with rocking/shaking. Membranes were washed three times with TBS-T. Secondary HRP-conjugated antibodies were diluted in TBS-T, added to membrane, and incubated for 1 to 2 h at room temperature with shaking. Membranes were washed five times with TBS-T and visualized with ECL (Thermo Scientific 34080) and exposed on film as needed. To determine loading, the membrane was stripped with Restore Plus Western stripping buffer (Thermo Scientific 46430) for 10 min and washed twice with TBS-T. The membrane was blocked again in 3% BSA in TBS-T for at least 1 h. Anti-actin HRP conjugate was added in TBS-T and incubated for  $\sim 1$  h at room temperature with shaking. The membrane was then washed five times with TBS-T and visualized as above. Antibodies used were goat anti-mouse ADAM9 (R&D Systems AF949; 1:1,000 dilution, 3% BSA blocking buffer), rabbit anti-human ADAM9 (Cell Signaling 2099; 1:1,000



dilution, 5% milk blocking buffer), anti-actin HRP conjugate (Santa Cruz sc-1616; 1:2,000 dilution, 3% BSA blocking buffer), anti-goat IgG HRP (1:2,000 dilution; R&D Systems HAF109), and anti-rabbit IgG HRP (1:5,000 dilution; Vector Labs PI1000).

**Statistical analysis.** Differences in the means of data were compared using unpaired, two-tailed Student's *t* test. ANOVA was used when comparing multiple values. Significant differences were assumed for *P* values of <0.05. All statistical analyses were performed using GraphPad Prism software (version 7.0d; GraphPad, San Diego, CA).

## ACKNOWLEDGMENTS

We thank Melanie Trombly for assistance with manuscript preparation. We also thank Carl P. Blobel and Gisela Weskamp for generously providing the plasmids for the wild type and the E>A mutation and the ADAM9 KO mice.

Author contributions are as follows: J.P.W., A.L.B., E.A.K.-J., and R.W.F. designed the research; L.E.B., M.K., C.R.M., P.P.K., P.M., and D.L. performed the research; J.R.-Q. and C.A.O. contributed new reagents/analytic tools and contributed to data interpretation; L.E.B., J.P.W., E.A.K.-J., A.L.B., and R.W.F. contributed to the analysis and wrote the paper.

We have no conflicts of interest to report.

Funding was as follows: American Heart Association-Myocarditis Foundation (18POST34030152) to L.E.B.; NIH NIAID (T32 AI095213) to C.R.M.; NIH NIAID (R01 AI116920) to J.P.W.; Burroughs Wellcome Foundation, Bill and Melinda Gates Foundation, Gilead Sciences Inc., and NIAID (R01 AI091786) to A.L.B.; and NIH NIAID (R01 AI111475), Flight Attendants Medical Research Institute grant (CIA123046), The Brigham and Women's Hospital-Lovelace Respiratory Research Institute Consortium, and Department of Defense (Congressional Directed Medical Research Programs) grant (PR152060) to C.A.O.

## REFERENCES

- Carocci M, Bakkali-Kassimi L. 2012. The encephalomyocarditis virus. *Virulence* 3:351–367. <https://doi.org/10.4161/viru.20573>.
- Helwig FC, Schmidt CH. 1945. A filter-passing agent producing interstitial myocarditis in anthropoid apes and small animals. *Science* 102: 31–33. <https://doi.org/10.1126/science.102.2637.31>.
- Murnane TG, Craighead JE, Mondragon H, Shelokov A. 1960. Fatal disease of swine due to encephalomyocarditis virus. *Science* 131: 498–499.
- Canelli E, Luppi A, Lavazza A, Lelli D, Sozzi E, Martin AMM, Gelmetti D, Pascotto E, Sandri C, Magnone W, Cordioli P. 2010. Encephalomyocarditis virus infection in an Italian zoo. *Virology* 404:1743–422X-7-64. <https://doi.org/10.1186/1743-422X-7-64>.
- Maurice H, Nielsen M, Brocchi E, Nowotny N, Kassimi LB, Billinis C, Loukaides P, O'Hara RS, Koenen F. 2005. The occurrence of encephalomyocarditis virus (EMCV) in European pigs from 1990 to 2001. *Epidemiol Infect* 133:547–557.
- Reddacliff LA, Kirkland PD, Hartley WJ, Reece RL. 1997. Encephalomyocarditis virus infections in an Australian zoo. *J Zoo Wildl Med* 28: 153–157.
- Billinis C. 2009. Encephalomyocarditis virus infection in wildlife species in Greece. *J Wildl Dis* 45:522–526. <https://doi.org/10.7589/0090-3558-45.2.522>.
- Kluivers M, Maurice H, Vyt P, Koenen F, Nielsen M. 2006. Transmission of encephalomyocarditis virus in pigs estimated from field data in Belgium by means of RO. *Vet Res* 37:757–766. <https://doi.org/10.1051/vetres:2006035>.
- Acland HM, Littlejohns IR. 1975. Encephalomyocarditis virus infection of pigs. 1. An outbreak in New South Wales. *Aust Vet J* 51:409–415.
- Littlejohns IR, Acland HM. 1975. Encephalomyocarditis virus infection of pigs. 2. Experimental disease. *Aust Vet J* 51:416–422.
- Spyrou V, Maurice H, Billinis C, Papanastassopoulou M, Psalla D, Nielsen M, Koenen F, Papadopoulos O. 2004. Transmission and pathogenicity of encephalomyocarditis virus (EMCV) among rats. *Vet Res* 35:113–122. <https://doi.org/10.1051/vetres:2003044>.
- Craighead JE, Peralta PH, Shelokov A. 1963. Demonstration of encephalomyocarditis virus antibody in human sera from Panama. *Proc Soc Exp Biol Med* 114:500–503.
- Kirkland PD, Gleeson AB, Hawkes RA, Naim HM, Boughton CR. 1989. Human infection with encephalomyocarditis virus in New South Wales. *Med J Aust* 151:176–178.
- Smadel JE, Warren J. 1947. The virus of encephalomyocarditis and its apparent causation of disease in man. *J Clin Invest* 26:1197.
- Tesh RB. 1978. The prevalence of encephalomyocarditis virus neutralizing antibodies among various human populations. *Am J Trop Med Hyg* 27:144–149.
- Deutz A, Fuchs K, Nowotny N, Auer H, Schuller W, Stunzner D. 2003. Sero-epidemiological studies of zoonotic infections in hunters—comparative analysis with veterinarians, farmers, and abattoir workers. *Wien Klin Wochenschr* 115(Suppl 3):61–67.
- Czechowicz J, Huaman JL, Forshey BM, Morrison AC, Castillo R, Huaman A, Caceda R, Eza D, Rocha C, Blair PJ, Olson JG, Kochel TJ. 2011. Prevalence and risk factors for encephalomyocarditis virus infection in Peru. *Vector Borne Zoonotic Dis* 11:367–374. <https://doi.org/10.1089/vbz.2010.0029>.
- Oberste MS, Gotuzzo E, Blair P, Nix WA, Ksiazek TG, Comer JA, Rollin P, Goldsmith CS, Olson J, Kochel TJ. 2009. Human febrile illness caused by encephalomyocarditis virus infection, Peru. *Emerg Infect Dis* 15: 640–646. <https://doi.org/10.3201/eid1504.081428>.
- Adachi M, Amsterdam D, Brooks SE, Volk BW. 1975. Ultrastructural alterations of tissue cultures from human fetal brain infected with the E variant of EMC virus. *Acta Neuropathol* 32:133–142. <https://doi.org/10.1007/BF00689567>.
- Wellmann KF, Amsterdam D, Volk BW. 1975. EMC virus and cultured human fetal pancreatic cells. Ultrastructural observations. *Arch Pathol* 99:424–429.
- Exley MA, Bigley NJ, Cheng O, Shaulov A, Tahir SMA, Carter QL, Garcia J, Wang C, Patten K, Stills HF, Alt FW, Snapper SB, Balk SP. 2003. Innate immune response to encephalomyocarditis virus infection mediated by CD1d. *Immunology* 110:519–526. <https://doi.org/10.1111/j.1365-2567.2003.01779.x>.
- Feng Q, Langereis MA, Lork M, Nguyen M, Hato SV, Lanke K, Emdad L, Bhoopathi P, Fisher PB, Lloyd RE, van Kuppeveld FJM. 2014. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. *J Virol* 88:3369–3378. <https://doi.org/10.1128/JVI.02712-13>.
- Huang L, Xiong T, Yu H, Zhang Q, Zhang K, Li C, Hu L, Zhang Y, Zhang L, Liu Q, Wang S, He X, Bu Z, Cai X, Cui S, Li J, Weng C. 2017. Encephalomyocarditis virus 3C protease attenuates type I interferon production through disrupting the TANK-TBK1-IKKeppilon-IRF3 complex. *Biochem J* 474:2051–2065. <https://doi.org/10.1042/BCJ20161037>.

24. Porter FW, Bochkov YA, Albee AJ, Wiese C, Palmenberg AC. 2006. A picornavirus protein interacts with Ran-GTPase and disrupts nucleocytoplasmic transport. *Proc Natl Acad Sci U S A* 103:12417–12422. <https://doi.org/10.1073/pnas.0605375103>.
25. Feng Q, Langereis MA, van Kuppeveld FJ. 2014. Induction and suppression of innate antiviral responses by picornaviruses. *Cytokine Growth Factor Rev* 25:577–585. <https://doi.org/10.1016/j.cytogfr.2014.07.003>.
26. Amendola RS, Martin ACBM, Selistre-de-Araújo HS, Paula-Neto HA, Saldanha-Gama R, Barja-Fidalgo C. 2015. ADAM9 disintegrin domain activates human neutrophils through an autocrine circuit involving integrins and CXCR2. *J Leukoc Biol* 97:951–962. <https://doi.org/10.1189/jlb.3A0914-455R>.
27. Blobel CP. 2005. ADAMs: key components in EGFR signalling and development. *Nat Rev Mol Cell Biol* 6:32–43. <https://doi.org/10.1038/nrm1548>.
28. Dreytmueller D, Pruessmeyer J, Groth E, Ludwig A. 2012. The role of ADAM-mediated shedding in vascular biology. *Eur J Cell Biol* 91:472–485. <https://doi.org/10.1016/j.ejcb.2011.09.003>.
29. English WR, Siviter RJ, Hansen M, Murphy G. 2017. ADAM9 is present at endothelial cell-cell junctions and regulates monocyte-endothelial transmigration. *Biochem Biophys Res Commun* 493:1057–1062. <https://doi.org/10.1016/j.bbrc.2017.09.089>.
30. Hotoda N, Koike H, Sasagawa N, Ishiura S. 2002. A secreted form of human ADAM9 has an alpha-secretase activity for APP. *Biochem Biophys Res Commun* 293:800–805. [https://doi.org/10.1016/S0006-291X\(02\)00302-9](https://doi.org/10.1016/S0006-291X(02)00302-9).
31. Mygind KJ, Schwarz J, Sahgal P, Ivaska J, Kveiborg M. 2018. Loss of ADAM9 expression impairs beta1 integrin endocytosis, focal adhesion formation and cancer cell migration. *J Cell Sci* 131:jcs205393. <https://doi.org/10.1242/jcs.205393>.
32. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. 2000. Meltrin gamma (ADAM-9) mediates cellular adhesion through alpha(6)beta(1) integrin, leading to a marked induction of fibroblast cell motility. *J Cell Sci* 113:2319–2328.
33. Ohtsu H, Dempsey PJ, Eguchi S. 2006. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. *Am J Physiol Cell Physiol* 291:C1–C10. <https://doi.org/10.1152/ajpcell.00620.2005>.
34. Roychaudhuri R, Hergrueter AH, Polverino F, Lauch-Contereras ME, Gupta K, Borregaard N, Owen CA. 2014. ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. *J Immunol* 193:2469–2482. <https://doi.org/10.1049/jimmunol.1303370>.
35. Schlondorff J, Blobel CP. 1999. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. *J Cell Sci* 112:3603–3617.
36. Horiuchi K, Zhou HM, Kelly K, Manova K, Blobel CP. 2005. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. *Dev Biol* 283:459–471. <https://doi.org/10.1016/j.ydbio.2005.05.004>.
37. Weskamp G, Blobel CP. 1994. A family of cellular proteins related to snake venom disintegrins. *Proc Natl Acad Sci U S A* 91:2748–2751.
38. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP. 2009. ADAM9 is involved in pathological retinal neovascularization. *Mol Cell Biol* 29:2694–2703. <https://doi.org/10.1128/MCB.01460-08>.
39. Howard L, Nelson KK, Maciewicz RA, Blobel CP. 1999. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. *J Biol Chem* 274:31693–31699. <https://doi.org/10.1074/jbc.274.44.31693>.
40. Inoue D, Reid M, Lum L, Krättschmar J, Weskamp G, Myung YM, Baron R, Blobel CP. 1998. Cloning and initial characterization of mouse meltrin beta and analysis of the expression of four metalloprotease-disintegrins in bone cells. *J Biol Chem* 273:4180–4187. <https://doi.org/10.1074/jbc.273.7.4180>.
41. Parry DA, Toomes C, Bida L, Danciger M, Towns KV, McKibbin M, Jacobson SG, Logan CV, Ali M, Bond J, Chance R, Swendeman S, Daniele LL, Springell K, Adams M, Johnson CA, Booth AP, Jafri H, Rashid Y, Banin E, Strom TM, Farber DB, Sharon D, Blobel CP, Pugh EN, Pierce EA, Inglehearn CF. 2009. Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice. *Am J Hum Genet* 84:683–691. <https://doi.org/10.1016/j.ajhg.2009.04.005>.
42. Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, Blackburn RK, Weskamp G, Tempst P, Blobel CP. 1999. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. *J Biol Chem* 274:3531–3540. <https://doi.org/10.1074/jbc.274.6.3531>.
43. Weskamp G, Cai H, Brodie TA, Higashiyama S, Manova K, Ludwig T, Blobel CP. 2002. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. *Mol Cell Biol* 22:1537–1544.
44. Weskamp G, Kratzschmar J, Reid MS, Blobel CP. 1996. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. *J Cell Biol* 132:717–726.
45. Takeda S. 2016. ADAM and ADAMTS family proteins and snake venom metalloproteinases: a structural overview. *Toxins (Basel)* 8:E155. <https://doi.org/10.3390/toxins8050155>.
46. Wong E, Maretzky T, Peleg Y, Blobel CP, Sagi I. 2015. The functional maturation of a disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site. *J Biol Chem* 290:12135–12146. <https://doi.org/10.1074/jbc.M114.624072>.
47. Lewandowski U, Wortelkamp S, Lohrig K, Zahedi RP, Wolters DA, Walter U, Sickmann A. 2009. Platelet membrane proteomics: a novel repository for functional research. *Blood* 114:e10–e19. <https://doi.org/10.1182/blood-2009-02-203828>.
48. Nagaraj N, Wisniewski JR, Geiger T, Cox J, Kircher M, Kelso J, Pääbo S, Mann M. 2011. Deep proteome and transcriptome mapping of a human cancer cell line. *Mol Syst Biol* 7:548. <https://doi.org/10.1038/msb.2011.81>.
49. Zeiler M, Moser M, Mann M. 2014. Copy number analysis of the murine platelet proteome spanning the complete abundance range. *Mol Cell Proteomics* 13:3435–3445. <https://doi.org/10.1074/mcp.M114.038513>.
50. Zhang P, Shen M, Fernandez-Patron C, Kassiri Z. 2016. ADAMs family and relatives in cardiovascular physiology and pathology. *J Mol Cell Cardiol* 93:186–199. <https://doi.org/10.1016/j.yjmcc.2015.10.031>.
51. Han J, Perez JT, Chen C, Li Y, Benitez A, Kandasamy M, Lee Y, Andrade J, tenOever B, Manicassamy B. 2018. Genome-wide CRISPR/Cas9 screen identifies host factors essential for influenza virus replication. *Cell Rep* 23:596–607. <https://doi.org/10.1016/j.celrep.2018.03.045>.
52. Perreira JM, Meraner P, Brass AL. 2016. Functional genomic strategies for elucidating human-virus interactions: will CRISPR knockout RNAi and haploid cells? *Adv Virus Res* 94:1–51. <https://doi.org/10.1016/bs.aivir.2015.11.001>.
53. Savidis G, McDougall WM, Meraner P, Perreira JM, Portmann JM, Trincucci G, John SP, Aker AM, Renzette N, Robbins DR, Guo Z, Green S, Kowalik TF, Brass AL. 2016. Identification of Zika virus and dengue virus dependency factors using functional genomics. *Cell Rep* 16:232–246. <https://doi.org/10.1016/j.celrep.2016.06.028>.
54. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen T, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 343:84–87. <https://doi.org/10.1126/science.1247005>.
55. McDougall WM, Perreira JM, Reynolds EC, Brass AL. 2018. CRISPR genetic screens to discover host-virus interactions. *Curr Opin Virol* 29:87–100. <https://doi.org/10.1016/j.coviro.2018.03.007>.
56. Jin YM, Pardoe IU, Burness AT, Michalak TI. 1994. Identification and characterization of the cell surface 70-kilodalton sialoglycoprotein(s) as a candidate receptor for encephalomyocarditis virus on human nucleated cells. *J Virol* 68:7308–7319.
57. Hammoumi S, Guy M, Eloit M, Bakkali-Kassimi L. 2012. Encephalomyocarditis virus may use different pathways to initiate infection of primary human cardiomyocytes. *Arch Virol* 157:43–52. <https://doi.org/10.1007/s00705-011-1133-6>.
58. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. 2005. Critical function for ADAM9 in mouse prostate cancer. *Cancer Res* 65:9312–9319. <https://doi.org/10.1158/0008-5472.CAN-05-1063>.
59. Ma H, Dang Y, Wu Y, Jia G, Anaya E, Zhang J, Abraham S, Choi J-G, Shi G, Qi L, Manjunath N, Wu H. 2015. A CRISPR-based screen identifies genes essential for West-Nile-virus-induced cell death. *Cell Rep* 12:673–683. <https://doi.org/10.1016/j.celrep.2015.06.049>.
60. Zhang R, Miner JJ, Gorman MJ, Rausch K, Ramage H, White JP, Zuiani A, Zhang P, Fernandez E, Zhang Q, Dowd KA, Pierson TC, Cherry S, Diamond MS. 2016. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. *Nature* 535:164–168. <https://doi.org/10.1038/nature18625>.
61. Heaton BE, Kennedy EM, Dumm RE, Harding AT, Sacco MT, Sachs D, Heaton NS. 2017. A CRISPR activation screen identifies a pan-avian



- influenza virus inhibitory host factor. *Cell Rep* 20:1503–1512. <https://doi.org/10.1016/j.celrep.2017.07.060>.
62. Huber SA. 1994. VCAM-1 is a receptor for encephalomyocarditis virus on murine vascular endothelial cells. *J Virol* 68:3453–3458.
  63. Dreytmueller D, Theodorou K, Donners M, Ludwig A. 2017. Fine tuning cell migration by a disintegrin and metalloproteinases. *Mediators Inflamm* 2017:9621724. <https://doi.org/10.1155/2017/9621724>.
  64. Lin CY, Cho CF, Bai ST, Liu JP, Kuo TT, Wang LJ. 2017. ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. *Sci Rep* 7:15108. <https://doi.org/10.1038/s41598-017-15159-1>.
  65. Seals DF, Courtneidge SA. 2003. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev* 17:7–30. <https://doi.org/10.1101/gad.1039703>.
  66. Andreev DE, Fernandez-Miragall O, Ramajo J, Dmitriev SE, Terenin IM, Martinez-Salas E, Shatsky IN. 2007. Differential factor requirement to assemble translation initiation complexes at the alternative start codons of foot-and-mouth disease virus RNA. *RNA* 13:1366–1374. <https://doi.org/10.1261/rna.469707>.
  67. Pilipenko EV, Pestova TV, Kolupaeva VG, Khitrina EV, Poperechnaya AN, Agol VI, Hellen CU. 2000. A cell cycle-dependent protein serves as a template-specific translation initiation factor. *Genes Dev* 14:2028–2045.
  68. Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Matthews S, Goodfellow IG, Curry S. 2007. Structural insights into the transcriptional and translational roles of Ebp1. *EMBO J* 26:3936–3944. <https://doi.org/10.1038/sj.emboj.7601817>.
  69. Zhang Y, Lu Y, Zhou H, Lee M, Liu Z, Hassel BA, Hamburger AW. 2008. Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice. *BMC Cell Biol* 9:69. <https://doi.org/10.1186/1471-2121-9-69>.
  70. Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM, Hamburger AW. 2008. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. *Mol Cancer Ther* 7:3176–3186. <https://doi.org/10.1158/1535-7163.MCT-08-0526>.
  71. Zhang Y, Akinmade D, Hamburger AW. 2008. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. *Cancer Lett* 265:298–306. <https://doi.org/10.1016/j.canlet.2008.02.024>.
  72. Akinmade D, Talukder AH, Zhang Y, Luo WM, Kumar R, Hamburger AW. 2008. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells. *Br J Cancer* 98:1132–1140. <https://doi.org/10.1038/sj.bjc.6604261>.
  73. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* 301:640–643. <https://doi.org/10.1126/science.1087262>.
  74. Brass AL, Huang I-C, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* 139:1243–1254. <https://doi.org/10.1016/j.cell.2009.12.017>.